Emily Blyth

Featured in: Favicon

nature.com Favicon

biomedcentral.com Favicon

ascopubs.org Favicon

biorxiv.org Favicon

lowestoftjournal.co.uk Favicon

onlinelibrary.wiley.com Favicon

genomebiology.biomedcentral.com Favicon

Articles

Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study

Mar 29, 2024 | ascopubs.org | John Byrd |Adam S. Kittai |David Bond |Emily Blyth

We performed an international multicenter retrospective study of patients with RT who received CAR-T. Patient, disease, and treatment characteristics were summarized using descriptive statistics, and modeling analyses were used to determine association with progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated from the date of CAR-T infusion. Sixty-nine patients were identified. The median age at CAR-T infusion was 64 years (range, 27-80).
CAR+ and CAR− T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies - Nature Communications

Nov 27, 2023 | nature.com | Curtis Cai |Mandeep Singh |Ira W. Deveson |James Ferguson |Timothy Amos |Robert Balderas | +3 more

AbstractChimeric antigen receptor (CAR) T cell therapy is effective in treating B cell malignancies, but factors influencing the persistence of functional CAR+ T cells, such as product composition, patients’ lymphodepletion, and immune reconstitution, are not well understood.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →